Mr. James Passin reports

BIOVAXYS TECHNOLOGY CORP. CLOSES DEBT SETTLEMENT TRANSACTION

Further to the news release dated Nov. 14, 2025, Biovaxys Technology Corp. has issued 1,792,387 common shares in the capital of the company at a deemed value of 23 cents per settlement share in full and final settlement of accrued and outstanding indebtedness in the aggregate amount of $412,249.

All securities issued in connection with the debt settlement are subject to a statutory hold period of four months from the date of issuance in accordance with applicable securities legislation.

About Biovaxys Technology Corp.

Biovaxys, a biopharmaceutical company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix tumour cell construct platform for treating cancers, infectious disease, antigen desensitization for food allergy and other immunological diseases. Through a differentiated mechanism of action, the DPX platform delivers instruction to the immune system to generate a specific, robust and persistent immune response. The company's clinical-stage pipeline includes maveropepimut-S, based on the DPX platform and in phase 2B clinical development for advanced relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer. MVP-S delivers antigenic peptides from survivin, a well-recognized cancer antigen commonly overexpressed in advanced cancers, and also delivers an innate immune activator and a universal CD4 T-cell helper peptide. MVP-S has been well tolerated and has demonstrated defined clinical benefit in multiple cancer indications, as well as the activation of a targeted and sustained, survivin-specific anti-tumour immune response. Biovaxys is also developing DPX+SurMAGE, a dual-targeted immunotherapy combining antigenic peptides for both the survivin and MAGE-A9 cancer proteins to elicit immune responses to these two distinct cancer antigens simultaneously, DPX-RSV for respiratory syncytial virus, DPX+rPA for peanut allergy prophylaxis and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix neoantigen tumour cell construct platform for refractive late-stage ovarian cancer.

Biovaxys common shares are listed on the Canadian Securities Exchange under the stock symbol BIOV and trade on the Frankfurt bourse and in the United States on the OTC Markets.

We seek Safe Harbor.